Paradigm Biopharmaceuticals Ltd's (ASX:PAR) CEO Paul Rennie speaks to Proactive's Andrew Scott after announcing they've initiated a Phase II clinical trial of subcutaneous injectable Pentosan Polysulphate Sodium (iPPS), in patients with the ultra-rare orphan disease Mucopolysaccharidosis Type 1 (MPS-1). The Phase II trial will be Paradigm’s first in MPS-I patients and will investigate treatment in a population, including pediatric patients.
Paradigm Biopharma CEO 'buoyed, enthusiastic and proud' as it begins dosing in Phase II MPS trial
Quick facts: Paradigm Biopharmaceuticals Ltd
Price: 2.48 AUD
Market Cap: $560.12 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...FOR OUR FULL DISCLAIMER CLICK HERE